SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing sovereign-AI demand and growth in customized software, is reinforcing Palantirs AI growth story as the stock reaches fresh highs. Bulls are celebrating the breakout and speculating about a short squeeze, while skeptics warn that the valuation is stretched and the rally could pull back.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares sold off sharply after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, raising fears that it could eventually compete with established wireless carriers. Traders are divided between seeing a lasting competitive threat and viewing the reaction as excessive, arguing that building a capable terrestrial network would take substantial time and investment.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally is drawing attention to Starknets privacy and Bitcoin DeFi push, including strkBTC and STRK20, alongside its post-quantum security narrative. Traders are largely bullish on the technology and momentum, while some remain wary of token unlocks and selling pressure.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoins choppy pullback and struggle to break above a key psychological level are driving discussion, with many traders describing weak or stagnant price action and warning of further downside. Others view the dip as an accumulation opportunity and expect a rebound alongside broader crypto-market strength.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff and underperformance versus U.S. airline peers are driving discussion, with traders citing oil and fuel-cost uncertainty and speculating about shorting or selling pressure after the share bid. Bears see further downside, while bulls point to buybacks and Aeroplans value as reasons for optimism.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

A report of a planned NIH-backed push to accelerate personalized cancer vaccines has lifted vaccine stocks, including BioNTech. Traders are discussing the sector rally and BioNTechs oncology pipeline, while some question why BNTX is lagging Moderna.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

AMZNs sharp rally has traders focused on whether it can break through the closely watched $260 area, with bullish chatter around heavy call buying and a potential technical breakout. Others warn the move could stall or retrace, pointing to resistance and the stocks choppy trading.

Fortinet, Inc. provides cybersecurity solutions to a variety of businesses, such as enterprises, communication service providers, government organizations, and small to medium-sized businesses. Its product portfolio includes network security, secure access service edge, enterprise networking, security operations, application security, and operational technology. The company was founded by Ken Xie and Michael Xie in November 2000 and is headquartered in Sunnyvale, CA.

Fortinet Inc

Fortinet is drawing attention amid a strong cybersecurity-sector rally, with traders linking demand to AI-related security risks and noting its run to new highs. The community is split between bullish momentum views and concerns that stretched valuations and light trading volume could leave the move vulnerable to a pullback.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers sharp selloff and persistent underperformance versus other space stocks dominate the discussion, with traders blaming financing and potential dilution concerns around a convertible-note offering. Bearish frustration over management and cash use contrasts with some traders viewing the decline as a buying opportunity.

WorldFinancial

Discussion centers on the OCCs preliminary conditional approval for a World Liberty trust bank tied to its USD1 stablecoin, which bullish traders see as a potential source of utility and demand for WLFI. Skeptics counter that the token has lagged other crypto assets and raise concerns about Trump-family monetization and selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial

Most multiple sclerosis (“MS”) drugs work by quieting the immune system. A new partnership shines the spotlight on a different approach — protecting the nerve’s own insulation — and sets up that treatment for a rigorous clinical test. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative and metabolic disorders, has signed a [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) entered into a Study Start-Up Agreement (&#8220;SUA&#8221;) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (&#8220;Lucid-MS&#8221;) for multiple sclerosis (&#8220;MS&#8221;). The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM),&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman &#38; Renshaw&#160;initiated&#160;coverage of the company with a Buy rating and&#160;a&#160;$8 price target. The research report was led by Michael G. King Jr., director of research and senior [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma&#160;(NASDAQ: QNTM)&#160;a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual&#160;ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated&#160;on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM)&#160;received a ‘Buy’ rating from&#160;Rodman &#38; Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous […]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;reported second-quarter 2026 financial and operational results, including a 53% year-over-year reduction in operating expenses to $2.29 million and a 47% decrease in general and administrative expenses to $1.76 million. Combined cash, cash equivalents and digital [&#8230;]

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis

This article has been disseminated on behalf of&#160;Quantum BioPharma Ltd.&#160;and may include paid advertising. Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and&#160;Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM)&#160;is one of the companies [&#8230;]

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd. - Ordinary Shares - Class B (Sub Voting)

Why Did QNTM Stock Pop In Pre-Market Today?

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.94
Prev Close	$3.11
Open	$3.11
Dividend Yield	0.00%
50-Day Moving Average	$3.38
Beta	1.23
Avg. Volume	199,615.06
PE Ratio	-0.52

52-Week High	$16.36
52-Week Low	$2.07
Market Capitalization	$25.15M
EPS (Annual)	-$7.97
Price to Book	2.80
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

QNTM Fundamentals